IBS-C薬のヨーロッパ市場2020-2152

◆英語タイトル:EUROPE IBS-C DRUG MARKET FORECAST 2020-2028
◆商品コード:INK20MY203
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年2月
◆ページ数:130
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:ヨーロッパ
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGSThe IBS-C drug market in Europe is predicted to register a CAGR of 9.38% during the estimated period, 2020-2028. Europe has the largest market share in the market. The demand for the market is growing, due to the highest number of patients suffering from IBS in the region.

MARKET INSIGHTS
In order to survey the Europe IBS- C drug market further, the European region is segregated into countries such as France, Poland, Italy, Belgium, Russia, the UK, Germany, and the rest of Europe that include countries like Spain and others. The Russian pharmaceutical industry is being considered by US exporters, and has huge potential, and can be distinguished into over the counter (OTC) medicines and prescription drugs. The pharmaceutical industry accounts for 1.2% of GDP and 22.1% of Russia’s healthcare expenditure. Prescription drug sales dominated sales until 2018, which represented 62.3% of sales. In Belgium, healthcare expenditure accounted for 10% of GDP in 2016 and remained stable over the years. In order to ensure good quality and effective medicines used currently, the pharmaceutical industry is heavily regulated. In countries like Poland, the growing elderly population and the rise in the number of gastrointestinal diseases and colorectal cancer are expected to fuel the overall growth of the market. Though Poland’s pharmaceutical market lags behind most Western European nations, the market records steady growth, owing to the stability and bright outlook of the country that attracts most global pharmaceutical companies. In Spain, IBD affects 7.8% of the population and twice the number of women compared to men.

COMPETITIVE INSIGHTS
AstraZeneca, Abbott Laboratories, Ferring BV, The Menarini Group, Bama-Geve, S.L.U., etc. are some of the major companies operating in the market.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
3.2.2. IBS CAN BE A HERITABILITY ISSUE
3.2.3. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
3.3. KEY RESTRAINTS
3.3.1. STRICT FDA REGULATIONS
3.3.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. REGULATORY FRAMEWORK
5. MARKET BY PRESCRIPTION TYPE
5.1. PRESCRIBED
5.1.1. BRANDED
5.1.2. GENERIC
5.2. OVER THE COUNTER
6. MARKET BY DRUG TYPE
6.1. LUBIPROSTONE
6.2. LINACLOTIDE
6.3. STIMULANT LAXATIVES
6.3.1. BISACODYL
6.3.2. SENNA
6.4. OSMOTIC LAXATIVES
6.4.1. LACTULOSE
6.4.2. POLYETHYLENE GLYCOL
6.5. OTHER DRUG TYPES
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. UNITED KINGDOM
7.1.2. GERMANY
7.1.3. FRANCE
7.1.4. ITALY
7.1.5. RUSSIA
7.1.6. BELGIUM
7.1.7. POLAND
7.1.8. REST OF EUROPE
8. COMPANY PROFILES
8.1. CATALENT PHARMACEUTICALS SOLUTIONS
8.2. ABBOTT LABORATORIES
8.3. NOVARTIS PHARMA AG
8.4. ASTELLAS PHARMACEUTICALS
8.5. ARDELYX, INC.
8.6. SYNTHETIC BIOLOGICS, INC.
8.7. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
8.8. BAMA-GEVE, SLU
8.9. FERRING BV
8.10. IRONWOOD PHARMACEUTICALS, INC.
8.11. SALIX PHARMACEUTICALS LTD.
8.12. NORGINE B.V.
8.13. PROMETHEUS LABORATORIES, INC.
8.14. ALBIREO PHARMA, INC.
8.15. YUHAN CORP.
8.16. ASTRAZENECA PLC
8.17. THE MENARINI GROUP
8.18. ONO PHARMACEUTICAL CO. LTD.
8.19. ACTAVIS NORDIC A/S

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – IBS-C DRUG
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: EUROPE IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 4: EUROPE IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 5: EUROPE IBS-C DRUG MARKET, BY PRESCRIBED, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 6: EUROPE IBS-C DRUG MARKET, BY PRESCRIBED, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 7: PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 8: EUROPE IBS-C DRUG MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: EUROPE IBS-C DRUG MARKET, BY DRUG TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 10: PRODUCT PROFILE (LUBIPROSTONE)
TABLE 11: PRODUCT PROFILE (LINACLOTIDE)
TABLE 12: EUROPE IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 13: EUROPE IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 14: PRODUCT PROFILE (BISACODYL)
TABLE 15: PRODUCT PROFILE (SENNA)
TABLE 16: EUROPE IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 17: EUROPE IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 18: PRODUCT PROFILE (LACTULOSE)
TABLE 19: PRODUCT PROFILE (POLYETHYLENE GLYCOL)
TABLE 20: PRODUCT PROFILE (PSYLLIUM)
TABLE 21: EUROPE IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 22: EUROPE IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
LIST OF FIGURES
FIGURE 1: DRUGS PULLED OFF FROM THE MARKET
FIGURE 2: KEY INVESTMENT INSIGHTS
FIGURE 3: PORTER’S FIVE FORCE ANALYSIS
FIGURE 4: OPPORTUNITY MATRIX
FIGURE 5: VENDOR LANDSCAPE
FIGURE 6: EUROPE IBS-C DRUG MARKET, GROWTH POTENTIAL, BY PRESCRIPTION TYPE, IN 2019
FIGURE 7: EUROPE IBS-C DRUG MARKET, PRESCRIBED, 2020-2028 (IN $ MILLION)
FIGURE 8: EUROPE IBS-C DRUG MARKET, BRANDED, 2020-2028 (IN $ MILLION)
FIGURE 9: EUROPE IBS-C DRUG MARKET, GENERIC, 2020-2028 (IN $ MILLION)
FIGURE 10: EUROPE IBS-C DRUG MARKET, OVER THE COUNTER, 2020-2028 (IN $ MILLION)
FIGURE 11: EUROPE IBS-C DRUG MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2019
FIGURE 12: EUROPE IBS-C DRUG MARKET, LUBIPROSTONE, 2020-2028 (IN $ MILLION)
FIGURE 13: EUROPE IBS-C DRUG MARKET, LINACLOTIDE, 2020-2028 (IN $ MILLION)
FIGURE 14: EUROPE IBS-C DRUG MARKET, STIMULANT LAXATIVES, 2020 -2028 (IN $ MILLION)
FIGURE 15: EUROPE IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)
FIGURE 16: EUROPE IBS-C DRUG MARKET, SENNA, 2020-2028 (IN $ MILLION)
FIGURE 17: EUROPE IBS-C DRUG MARKET, OSMOTIC LAXATIVES, 2020 -2028 (IN $ MILLION)
FIGURE 18: EUROPE IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)
FIGURE 19: EUROPE IBS-C DRUG MARKET, POLYETHYLENE GLYCOL, 2020-2028 (IN $ MILLION)
FIGURE 20: EUROPE IBS-C DRUG MARKET, OTHER DRUG TYPES, 2020 -2028 (IN $ MILLION)
FIGURE 21: EUROPE IBS-C DRUG MARKET, BY REGION, 2019 & 2028 (IN %)
FIGURE 22: UNITED KINGDOM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 23: GERMANY IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 24: FRANCE IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 25: ITALY IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 26: RUSSIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 27: BELGIUM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 28: POLAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 29: REST OF EUROPE IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[IBS-C薬のヨーロッパ市場2020-2152]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆